

## 6 Literatur

- 1) **Saarländisches Krebsregister , Berichtsjahr 1989**
- 2) Aeberhard P  
**Chirurgische Therapie des Mammakarzinoms**  
Symposium Mammakarzinom Sonderdruck Kantonsspital Aarau 1987, 65-75
- 3) Andreassen PA, Kjoller L, Christensen L, et al.  
**The urokinase-type plasminogen activator system in cancer metastasis: a review.**  
Int J Cancer (United States), Jul 3 1997, 72(1) p1-22
- 4) Badellino F., Canavese G., Catturich A., Vecchio C., Tomei D., Mereu P., Scala M  
**La chirurgia del carcinoma mammario. Dieci anni di attivita. [The surgery of breast carcinoma. 10 years of activity]**  
Minerva-Chir. 1997 May; 52(5): 531-48
- 5) Balaton AJ., Baviera EE., Galet B., Vaury P., Vuong PN  
**Immunohistochemical evaluation of estrogen and progesterone receptors on paraffin sections of breast carcinomas. Practical thoughts based on the study of 368 cases**  
Arch-Anat-Cytol-Pathol. 1995; 43(1-2): 93-100
- 6) Ball A  
**Specialist surgeons and survival in breast cancer. Treating a specified number of patients is no guarantee of quality**  
BMJ. 1996 Aug 24; 313(7055): 494-5
- 7) Ballard-Barbash R., Swanson CA.  
**Body weight: estimation of risk for breast and endometrial cancers.**  
Am-J-Clin-Nutr. 1996 Mar; 63(3 Suppl): 437S-441S
- 8) Bassler R; Bocker W; Hermanek P; Pickartz H; Prechtel K; Schauer A; Schnurch HG; Stegner HE  
**Die gegenwartige Situation des Gradings beim Mammakarzinom**  
Pathologie 1992 May;13(3):130-4 (ISSN: 0172-8113)
- 9) Bastert  
**Malignome der Mamma, Sonderdruck**  
Schmidt-Mathiesen : Klinik der Frauenheilkunde Urban & Schwarzenberg, München - Wien 1990 S 131 - 227
- 10) Baum M  
**Specialist surgeons and survival in breast cancer. Large differences in survival are not explained**  
BMJ. 1996 May 4; 312(7039): 1155

- 11) Beck T; Pollow K; Heubner A  
**Monoklonale Antikörper zum immunhistochemischen Nachweis des Östrogenrezeptor-Status am Gewebeschnitt primärer Mammakarzinome**  
Geburtshilfe Frauenheilkd 1986 Aug;46(8):490-4 (ISSN: 0016-5751)
- 12) Berry MG  
**An audit of outcome including patient satisfaction with immediate breast reconstruction performed by breast surgeons.**  
Ann R Coll Surg Engl, 1998 May
- 13) Bianco AR, Gallo C  
**Adjuvant therapy with tamoxifen in operable breast cancer, 10 year results of the Naples (GUN) study**  
Lancet 1988:1095-1099
- 14) Blair SL., O'Shea KE., Orr RK  
**Surgeon variability in treating nonpalpable breast cancer: surgical oncology as a value-added specialty.**  
Ann-Surg-Oncol. 1998 Jan-Feb; 5(1): 28-32
- 15) Bland KI., Menck HR., Scott-Conner CE., Morrow M., Winchester DJ., Winchester DP  
**The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States.**  
Cancer. 1998 Sep 15; 83(6): 1262-73
- 16) Bloom HJ, Field JR  
**Impact of tumor grade and host resistance on survival of women with breast cancer.**  
Cancer (United States), Dec 1971, 28(6) p1580-9
- 17) Bloom HJG, Richardson WW  
**Histological grading and prognosis in breast cancer.**  
Br J Cancer 1957; 11:359-377
- 18) Bonadonna G  
**Adjuvant castration versus adjuvant chemotherapy**  
Int J Radiat Oncol Biol Phys (United States), Sep-Oct 1978, 4(9-10) p918-9
- 19) Bonadonna G, Brusaporino E, Vaagussa P, Rossi A, Brugnatelli L, Brambilla C, Tancini G  
**Combination chemotherapy as an adjuvant treatment in operable breast cancer**  
Engl J Med 1976; 294: 405-410.
- 20) Bonadonna G, Vaagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M,  
**Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.**  
Breast Cancer Res Treat 5, 1985: 95-115.
- 21) Bonadonna G:  
**Adjuvant chemotherapy in node-negative breast cancer, NCI consensus conference.**  
Eur J Cancer 1990; 26: 844-845.

- 22) Bonnema J., van-Wersch AM., van-Geel AN., Pruyn JF., Schmitz PI., Paul MA., Wiggers T  
**Medical and psychosocial effects of early discharge after surgery for breast cancer: randomised trial.**  
BMJ. 1998 Apr 25; 316(7140): 1267-71
- 23) Bremond A  
**Surgeon's role in the screening of breast cancer (editorial)**  
Ann-Chir. 1996; 50(2): 103-5
- 24) Bruntsch U , Gallmeier  
**Adjuvante Behandlung des Mammakarzinoms**  
Münch med Wschr 1992 ; 134,13:199-204
- 25) Burgess CC., Ramirez AJ., Richards MA., Love SB  
**Who and what influences delayed presentation in breast cancer?**  
Br-J-Cancer. 1998 Apr; 77(8): 1343-8
- 26) Burke CC., Zabka CL., McCarver KJ., Singletary SE  
**Patient satisfaction with 23-hour "short-stay" observation following breast cancer surgery.**  
Oncol-Nurs-Forum. 1997 May; 24(4): 645-51
- 27) Burns RB., Freund KM., Moskowitz MA., Kasten L., Feldman H., McKinlay JB  
**Physician characteristics: do they influence the evaluation and treatment of breast cancer in older women?**  
Am-J-Med Oct 1997 ; 103 : 263-269
- 28) Carlomagno C, Perrone F, Gallo C, et al.  
**c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.**  
J Clin Oncol (United States), Oct 1996, 14(10) p2702-8
- 29) Casolo P., Mosca D., Amorotti C., Raspadori A., Drei B., Di-Blasio P., Colli G. et al.  
**La nostra esperienza nel trattamento chirurgico del carcinoma mammario iniziale. Risultati di uno studio prospettico su 204 casi. [Our experience in the surgical treatment of early breast cancer. Results of a prospective study of 204 cases]**  
Ann-Ital-Chir. 1997 Mar-Apr; 68(2): 195-204; discussion 204-5
- 30) Chabner E., Nixon A., Gelman R., Hetelekidis S., Recht A., Bornstein B., Connolly J., et al.  
**Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer.**  
J-Clin-Oncol. 1998 Jun; 16(6): 2045-51
- 31) Chang S., Hulka BS., Baird DD., Ingle JN., Newman B., Graham ML 2nd., Qaqish B  
**Breast cancer survival and the timing of tumor removal during the menstrual cycle.**  
Cancer-Epidemiol-Biomarkers-Prev. 1997 Nov; 6(11): 881-6
- 32) Chang-Claude J; Becher H; Hamann U; Schroeder-Kurth T  
**Risikoabschätzung für das familiäre Auftreten von Brustkrebs**  
Zentralbl Gynakol 1995;117(8):423-34 (ISSN: 0044-4197)

- 33) Charlson ME, Feinstein AR  
**Rapid growth rate in breast cancer: a confounding variable in adjuvant chemotherapy trials.**  
Lancet 1982; 1: 1343-1345
- 34) Chie WC., Chen CF., Lee WC., Chen CJ.  
**Body size and risk of pre- and postmenopausal breast cancer in Taiwan.**  
Anticancer-Res. 1996 Sep-Oct; 16(5B): 3129-3132
- 35) Chie WC., Li CY., Huang CS., Chang KJ., Lin RS  
**Body size as a factor in different ages and breast cancer risk in Taiwan.**  
Anticancer-Res. 1998 Jan-Feb; 18(1B): 565-70
- 36) Chie WC., Li CY., Huang CS., Chang KJ., Yen ML., Lin RS.  
**Oral contraceptives and breast cancer risk in Taiwan, a country of low incidence of breast cancer and low use of oral contraceptives.**  
Int-J-Cancer. 1998 Jul 17; 77(2): 219-23
- 37) Chlebowski RT  
**Dietary fat reduction in adjuvant breast cancer therapy**  
Salmon SE Adjuvant Therapy of Cancer VI. WB Saunders Company , Philadelphia  
London, 1990 : 357-362
- 38) Christiaens MR  
**Documentation of the surgical procedure: a tool for quality assessment for breast conservative treatment.**  
Anticancer-Res. 1996 Nov-Dec; 16(6C): 3955-8
- 39) Cleary MP., Maihle NJ.  
**The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer.**  
Proc-Soc-Exp-Biol-Med. 1997 Oct; 216(1): 28-43
- 40) Colditz GA, Hankinson SE, Hunter DJ, et al.  
**The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.**  
N Engl J Med (United States), Jun 15 1995, 332(24) p1589-93
- 41) Collaborative Group on Hormonal Factors in Breast Cancer  
**Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.**  
Lancet. 1996 Jun 22; 347(9017): 1713-27
- 42) Craft PS., Primrose JG., Lindner JA., McManus PR  
**Surgical management of breast cancer in Australian women in 1993: analysis of Medicare statistics**  
Med-J-Aust. 1997 Jun 16; 166(12): 626-9
- 43) Cummings FJ, Cray R  
**Tamoxifen versus placebo**  
NCI Monography Bethesda MD 1986; 1:119-123

- 44) Curran D., van-Dongen JP., Aaronson NK., Kiebert G., Fentiman IS., Mignolet F., Bartelink  
**Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801.**  
Eur-J-Cancer. 1998 Feb; 34(3): 307-14
- 45) D. Wallwiener  
**Moderne Mamma- Diagnostik und -Therapie: Prinzipien und Indikation der neoadjuvanten Therapie ( B24 )**  
Univ.- Frauenklinik Tübingen 2001
- 46) Deo SV., Shukla NK., Goel AK., Kishore J  
**Short stay surgery for breast cancer: an audit of an experience in a regional cancer centre in northern India.**  
Eur-J-Surg-Oncol. 1997 Aug; 23(4): 335-8
- 47) de-Sanjose S., Viladiu P., Cordon F., Vilardell L., Marcos R., Izquierdo A  
**Breast cancer and heredity: results of a population case-control study in Girona**  
Med-Clin-Barc. 1998 Mar 21; 110(10): 370-2
- 48) DiFronzo LA., O'Connell TX .  
**Breast cancer in pregnancy and lactation.**  
Surg-Clin-North-Am. 1996 Apr; 76(2): 267-78
- 49) Dixon JM., Leonard RC  
**Specialist surgeons and survival in breast cancer. A multidisciplinary approach is needed**  
BMJ. 1996 May 4; 312(7039): 1155-6
- 50) EBCTCG  
**Systemic treatment of early breast cancer by hormonal cytotoxic or immune therap**  
Lancet 1992; 339: 1-15, 71-85
- 51) Editorial  
**Ovarian ablation in early breast cancer: phoenix arisen?**  
Lancet 1992; 339 : 95-96
- 52) Ewertz, M.  
**Epidemiology of breast cancer : The Nordic cotribution**  
Eur-J-Surg. 1996 Feb; 162(2): 97-9
- 53) Ezzat A., Raja MA., Zwaan F., Brigden M., Rostom A., Bazarbashi S  
**The lack of age as a significant prognostic factor in non-metastatic breast cancer.**  
Eur-J-Surg-Oncol. 1998 Feb; 24(1): 23-7
- 54) Fisher B, Brown A, Wolmark N, et al.  
**Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial.**  
Ann Intern Med (United States), May 1987, 106(5) p649-54

- 55) Fisher B, Carbone P, Economou SG, et al  
**1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.**  
N Engl J Med (United States), Jan 16 1975, 292(3) p117-22
- 56) Fisher B, Costantino J, Redmond C  
**A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors**  
N Engl J Med (United States), Feb 23 1989, 320(8) p479-84
- 57) Fisher B, Redmond C, Fisher ER, et al.  
**Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.**  
J Clin Oncol (United States), Jul 1988, 6(7) p1076-87
- 58) Fisher B, Redmond C, Wickerham OL, Wolmarsh N, Bowman O, Couture J, Omitrov N,  
**A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor- negative tumors. (NSA8P 813)**  
N Engl J Med 1989; 320: 473-478.
- 59) Fisher CJ., Egan MK., Smith P Wicks K., Millis RR., Fentiman IS  
**Histopathology of breast cancer in relation to age.**  
Br-J-Cancer. 1997; 75(4): 593-6
- 60) Fisher ER, Gregorio R, Redmond C, et al.  
**Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4). I. Observations concerning the multicentricity of mammary cancer.**  
Cancer (United States), Jan 1975, 35(1) p247-54
- 61) Fisher ER, Gregorio RM, Redmond C, et al.  
**Pathologic findings from the national surgical adjuvant breast project. (Protocol no. 4). III. The significance of extranodal extension of axillary metastases.**  
Am J Clin Pathol (United States), Apr 1976, 65(4) p439-44
- 62) Fisher ER, Redmond C, Fisher B  
**Pathologic findings from the National Surgical Adjuvant Breast Project. VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation**  
Cancer (United States), Jan 15 1983, 51(2) p181-91
- 63) Forbes, JF.  
**The incidence of breast cancer: the global burden, public health considerations**  
Semin-Oncol. 1997 Feb; 24(1 Suppl 1): S1-20-S1-35
- 64) Fraser GE., Shavlik D  
**Risk factors, lifetime risk, and age at onset of breast cancer.**  
Ann Epidemiol, 7(6):375-82 1997 Aug

- 65) Friedrich M  
**MRI of the breast: state of the art.**  
Eur-Radiol. 1998; 8(5): 707-25
- 66) Funke I, Schraut W  
**Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.**  
J Clin Oncol (United States), Feb 1998, 16(2) p557-66
- 67) Furnival CM  
**Breast cancer: current issues in diagnosis and treatment**  
Aust-N-Z-J-Surg. 1997 Jan; 67(1): 47-58
- 68) Gerdes J, Lelle RJ, Pickartz H, et al.  
**Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.**  
J Clin Pathol (England), Sep 1986, 39(9) p977-80
- 69) Gerdes J, Schwab U, Lemke H, et al.  
**Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.**  
Int J Cancer (Denmark), Jan 15 1983, 31(1) p13-20
- 70) German Breast Cancer Study Group (GBSG).  
**Therapy of small breast cancer--four-year results of a prospective non-randomized study.**  
Breast-Cancer-Res-Treat. 1995 Apr; 34(1): 1-13
- 71) Giguere, JK .  
**Advances in diagnosis and therapies for breast cancer.**  
J-S-C-Med-Assoc. 1998 Jun; 94(6): 254-6
- 72) Gillis CR., Hole DJ  
**Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland**  
BMJ. 1996 Jan 20; 312(7024): 145-8
- 73) Goldhirsch A, Gelber RD, Castiglione M  
**The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group.**  
Ann Oncol (Netherlands), 1990, 1(3) p183-8
- 74) Goodwin JS., Freeman JL., Freeman D., Nattinger AB  
**Geographic variations in breast cancer mortality: do higher rates imply elevated incidence or poorer survival?**  
Am-J-Public-Health. 1998 Mar; 88(3): 458-60
- 75) Grosse A., Schreer I., Frischbier HJ., Maass H., Loening T., Bahnsen J  
**Results of breast conserving therapy for early breast cancer and the role of mammographic follow-up.**  
Int-J-Radiat-Oncol-Biol-Phys. 1997 Jul 1; 38(4): 761-7

- 76) Hacker N.  
**Breast Disease, a gynecologic perspective**  
Essentials of obstetrics and gynecology, (Edited by Hacker / Moore) - 3rd Edition, W.B. Saunders Company 1998 Philadelphia
- 77) Harbeck N , Look MP  
**uPA and PAI-1 ready for routine testing in primary breast cancer: Pooled analysis (n=8377) provides level-I evidence for clinical relevance**  
Proc ASCO
- 78) Harbeck N, Dettmar P, Thomssen C, et al.  
**Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.**  
Br J Cancer (Scotland), May 1999, 80(3-4) p419-26
- 79) Harms SE  
**MRI in breast cancer diagnosis and treatment.**  
Curr-Probl-Diagn-Radiol. 1996 Nov-Dec; 25(6): 193-215
- 80) Harris JR Morrow M  
**Adjuvant chemotherapy in breast cancer**  
De Vita VT, Hellman S Cancer - Principles and Practice of Oncology Lippincott, Philadelphia 1993: 1301-1323
- 81) Haward RA., Forman D  
**Specialist surgeons and survival in breast cancer. Observational studies are essential**  
BMJ. 1996 Aug 24; 313(7055): 494; discussion 495
- 82) Hemminki K., Vaitinen P.  
**Familial breast cancer in the family-cancer database.**  
Int-J-Cancer. 1998 Jul 29; 77(3): 386-91
- 83) Henderson JC. Harris JR  
**Cancer of the Breast. In : De Vita VT, Hellman S Cancer - Principles and Practice of Oncology.**  
Lippincott Philadelohia 1989:1197-1268
- 84) Hillner BE., McDonald MK., Penberthy L., Desch CE., Smith TJ., Maddux P., Glasheen WP., Retchin SM  
**Measuring standards of care for early breast cancer in an insured population**  
J-Clin-Oncol. 1997 Apr; 15(4): 1401-8
- 85) Holland R, Veling SH, Mravunac M, et al.  
**Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery.**  
Cancer (United States), Sep 1 1985, 56(5) p979-90
- 86) Holli K., Isola J  
**Effect of age on the survival of breast cancer patients.**  
Eur J Cancer, 33(3):425-8 1997 Mar



- 87) Holmberg L  
**Role of surgery in invasive breast cancer.**  
Acta-Oncol. 1995; 34(5): 625-8
- 88) Huang Z., Hankinson SE., Colditz GA., Stampfer MJ., Hunter DJ., Manson JE., et al.  
**Dual effects of weight and weight gain on breast cancer risk**  
JAMA, Nov. 1997; 278(17): 1407-1411
- 89) Iglehart JD., Miron A., Rimer BK., Winer EP., Berry D., Shildkraut MJ  
**Overestimation of hereditary breast cancer risk.**  
Ann-Surg. 1998 Sep; 228(3): 375-84
- 90) Ingle JN, Everson LK, Wieand HS, et al.  
**Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.**  
Cancer (United States), Apr 1 1989, 63(7) p1257-64
- 91) International Breast Cancer Study Group  
**Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients.**  
Annals of Oncology 1990; 1 : 30-35
- 92) Irwig L., Bennetts A  
**Quality of life after breast conservation or mastectomy: a systematic review**  
Aust-N-Z-J-Surg. 1997 Nov; 67(11): 750-4
- 93) Jänicke F  
**Adjuvante Strahlentherapie nach eingeschränkt radikaler Mastektomie**  
Tumorzentrum München : Empfehlungen zur Diagnostik, Therapie und Nachsorge.  
Manual Mammakarzinom, 5. Auflage 1994; 51-54
- 94) Janicke F, Prechtel A, Thomssen C, et al.  
**Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.**  
J Natl Cancer Inst (United States), Jun 20 2001, 93(12) p913-20
- 95) Kaaks R., Van-Noord PA., Den-Tonkelaar I., Peeters PJH., Riboli E., Grobbee DE  
**Breast-cancer incidence in relation to height, weight and body-fat distribution in the Dutch "DOM" cohort.**  
Int-J-Cancer. 1998 May 29; 76(5): 647-51
- 96) Kerr B., Foulkes WD., Cade D., Hadfield L., Hopwood P., Serruya C., Hoare E., Narod SA., Evans DG.  
**False family history of breast cancer in the family cancer clinic.**  
Eur-J-Surg-Oncol. 1998 Aug; 24(4): 275-9
- 97) Kilkenny JW 3rd., Bland KI  
**Surgery of breast cancer.**  
Curr-Opin-Oncol. 1997 Nov; 9(6): 520-6

- 98) Kini VR., White JR., Horwitz EM., Dmuchowski CF., Martinez AA., Vicini FA  
**Long term results with breast-conserving therapy for patients with early stage breast carcinoma in a community hospital setting.**  
Cancer. 1998 Jan 1; 82(1): 127-33
- 99) Kliukiene J., Andersen A  
**Survival of breast cancer patients in Lithuania and Norway, 1988-1992.**  
Eur-J-Cancer. 1998 Feb; 34(3): 372-7
- 100) Knief JJ  
**Das Mammakarzinom- eine medizingeschichtliche Studie.**  
Der Frauenarzt 1993; 34: 137-150
- 101) Kramer-S; Schulz-Wendtland-R; Hagedorn-K; Bautz-W; Lang-N  
**Magnetic resonance imaging and its role in the diagnosis of multicentric breast cancer.**  
Anticancer-Res. 1998 May-Jun; 18(3C): 2163-4
- 102) Kuerer HM., Cunningham JD., Brower ST., Tartter PI.  
**Breast carcinoma associated with pregnancy and lactation.**  
Surg-Oncol. 1997 Aug; 6(2): 93-8
- 103) La Rosa F., Patavino VM., Epifani AC., Petrinelli AM., Minelli L., Mastrandrea V  
**Ten-year survival and age at diagnosis of women with breast cancer from a population-based study in Umbria, Italy.**  
Tumori, 82(5):441-3 1996 Sep-Oct
- 104) Iber A, Bray D  
**Molekularbiologie der Zelle**  
3 Auflage, VCH-Verlag. Weinheim New York
- 105) Lee CH., Carter D  
**Detecting residual tumor after excisional biopsy of impalpable breast carcinoma: efficacy of comparing preoperative mammograms with radiographs of the biopsy specimen.**  
AJR-Am-J-Roentgenol. 1995 Jan; 164(1): 81-6
- 106) Ludwig breast cancer study group  
**Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy tor node-negative breast cancer**  
N Engl J Med 1989; 320: 491-496.
- 107) Maas H  
**Das primäre Mammakarzinom**  
Käser Friedber et al Gynäkologie und Geburtshilfe. Bd III/1 Thieme Verlag, Stuttgart-Heidelberg-New York, 1985 3.92-3.141
- 108) Macmillan RD., Purushotham AD., Mallon E., Love JG., George WD  
**Tumour bed positivity predicts outcome after breast-conserving surgery.**  
Br-J-Surg. 1997 Nov; 84(11): 1559-62

- 109) Magnusson C., Colditz G., Rosner B., Bergstrom R., Persson I  
**Association of family history and other risk factors with breast cancer risk (Sweden).**  
Cancer-Causes-Control. 1998 May; 9(3): 259-67
- 110) Mambo NC, Gallager HS  
**Carcinoma of the breast: the prognostic significance of extranodal extension of axillary disease.**  
Cancer (United States), May 1977, 39(5) p2280-5
- 111) McCarthy DO., Blamey RW., Robertson JF., Mitchell AK  
**A one-year audit of 255 operable breast cancers.**  
Eur-J-Surg-Oncol. 1997 Oct; 23(5): 399-402
- 112) McKinlay JB., Burns RB., Feldman HA., Freund KM., Irish JT., Kasten LE., Moskowitz MA  
**Physician variability and uncertainty in the management of breast cancer. Results from a factorial experiment.**  
Med-Care. 1998 Mar; 36(3): 385-96
- 113) Merkel DE.  
**Pregnancy and breast cancer.**  
Semin-Surg-Oncol. 1996 Sep-Oct; 12(5): 370-5
- 114) Meuret G  
**Mammakarzinom, Grundlagen, Diagnostik Therapie**  
Thieme Verlag, Stuttgart - Heidelberg 1. Auflage 1980
- 115) Miki Y, Swensen J, Shattuck-Eidens D, et al.  
**A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.**  
Science (United States), Oct 7 1994, 266(5182) p66-71
- 116) Minami Y., Ohuchi N., Taeda Y., Fukao A., Hisamichi S  
**Risk factors for benign breast disease according to histopathological type: comparisons with risk factors for breast cancer.**  
Jpn-J-Cancer-Res. 1998 Feb; 89(2): 116-23
- 117) Mirsky D., O'Brien SE., McCready D., Newman TE., Whelan TJ., Levine MN  
**Surgical management of early stage invasive breast cancer (stage I and II). Provincial Breast Disease Site Group.**  
Cancer-Prev-Control. 1997; 1(1): 10-7
- 118) Mitus J., Stelmach A., Reinfuss M., Skotnicki P., Walasek T  
**20-year survival in women with breast cancer**  
Przegl-Lek. 1997; 54(5): 300-1
- 119) Mohammed SN., Smith P., Hodgson SV., Fentiman IS., Miles DW., Barnes DM., Millis RR., Rubens RD  
**Family history and survival in premenopausal breast cancer.**  
Br-J-Cancer. 1998 Jun; 77(12): 2252-6

- 120) Moritz S., Bates T., Henderson SM., Humphreys S., Michell MJ  
**Variation in management of small invasive breast cancers detected on screening in the former south east Thames region: observational study.**  
BMJ. 1997 Nov 15; 315(7118): 1266-72
- 121) Morris AD., Morris RD., Wilson JF., White J., Steinberg S., Okunieff P., Arriagada R., et al.  
**Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival**  
Cancer-J-Sci-Am. 1997 Jan-Feb; 3(1): 6-12
- 122) Morrow M., Bucci C., Rademaker A  
**Medical contraindications are not a major factor in the underutilization of breast conserving therapy.**  
J-Am-Coll-Surg. 1998 Mar; 186(3): 269-74
- 123) Murphy M., Allen D., Key T., Thomas HV., Fentiman IS., Wang DY  
**Social, biological and reproductive characteristics of mothers of twins: implications for breast cancer risk.**  
Ann-Hum-Biol. 1998 Jan-Feb; 25(1): 77-85
- 124) Mutzner PA  
**Die Bedeutung der adjuvanten Chemotherapie beim primären lokalen Mammakarzinom**  
Bohmer ; Breast Cancer and Breast Reconstruction Thieme Verlag, Stuttgart-Heidelberg-New York, 1.Auflage 1982 38-43
- 125) Nagata C., Kawakami N., Shimizu H  
**Trends in the incidence rate and risk factors for breast cancer in Japan**  
Breast-Cancer-Res-Treat. 1997 May; 44(1): 75-82
- 126) Nissen-Meyer R, Host H, Kjellgren K, et al.  
**One short chemotherapy course given immediately after mastectomy , experience of the Scandinavian adjuvant chemotherapy study group**  
Colloque INSERM 1986; 137: 157-164
- 127) Norum J., Olsen JA., Wist EA  
**Lumpectomy or mastectomy? Is breast conserving surgery too expensive?**  
Breast-Cancer-Res-Treat. 1997 Aug; 45(1): 7-14
- 128) Obrist S., Sauter C Pestalozzi BC  
**Quality of treatment in operable breast carcinoma. Comparison of the years before 1987, 1987-1990 and 1991-1994**  
Schweiz-Med-Wochenschr. 1997 Aug 23; 127(34): 1371-9
- 129) Oksbjerg S., Mellekjær L., Johansen C  
**Incidence and mortality of breast cancer among women in Denmark 1943-1992**  
Ugeskr-Laeger. 1997 Nov 24; 159(48): 7134-40

- 130) Otten JD., van-Dijck JA., Peer PG., Straatman H., Verbeek AL., Mravunac M., Hendriks JH et al.  
**Long term breast cancer screening in Nijmegen, The Netherlands: the nine rounds from 1975-92.**  
J-Epidemiol-Community-Health. 1996 Jun; 50(3): 353-8
- 131) Paik S, Bryant J, Tan-Chiu E, et al.  
**HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.**  
J Natl Cancer Inst (United States), Dec 20 2000, 92(24) p1991-8
- 132) Pallud C  
**Breast cancer. Histology. Classification and prognosis**  
Soins. 1996 Sep(608): 11-2
- 133) Parl FF Dupont WD  
**A retrospective cohort study of histologic risk factors in breast cancer patients.**  
Cancer 1986; 50: 2410-2416
- 134) Paterok EM; Siebzehnruhl E; Meyer M.  
**Altersspezifische und alterskorrigierte Mortalität gynäkologischer Karzinome--  
einschl. Mamma-Karzinom**  
Geburtshilfe Frauenheilkd 1995 Apr;55(4):177-81 (ISSN: 0016-5751)
- 135) Persson I., Bergstrom R., Barlow L., Adami HO  
**Recent trends in breast cancer incidence in Sweden**  
Br-J-Cancer. 1998; 77(1): 167-9
- 136) Piccart MJ, Di Leo A, Hamilton A  
**HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?**  
Eur J Cancer (England), Sep 2000, 36(14) p1755-61
- 137) Potosky AL., Merrill RM., Riley GF., Taplin SH., Barlo W., Fireman BH., Ballard-Barbash R  
**Breast cancer survival and treatment in health maintenance organization and fee-for-service settings**  
J-Natl-Cancer-Inst. 1997 Nov 19; 89(22): 1683-91
- 138) Pujol P., Galtier-Dereure F., Bringer J.  
**Obesity and breast cancer risk**  
Hum-Reprod. 1997 Oct; 12 Suppl. 1: 116-25
- 139) Raabe NK., Fossa SD., Karesen-R  
**Primary invasive breast cancer in Oslo 1980-89. A population based study of 1942 unselected patients treated by radical surgery**  
Tidsskr-Nor-Laegeforen. 1997 Oct 30; 117(26): 3778-83
- 140) Raabe NK., Kaarsen R., Fossa SD  
**Analysis of adjuvant treatment in postmenopausal patients with stage II invasive breast carcinoma--a pattern of care study and quality assurance of 431 consecutive patients in Oslo 1980-1989.**  
Acta-Oncol. 1997; 36(3): 255-60

- 141) Ranieri E., D'Andrea MR., D'Alessio A., Bergomi S., Caprio G., Calabrese GB., Virno F  
**Ultrasound in the detection of breast cancer associated with isolated clustered microcalcifications, mammographically identified.**  
Anticancer-Res. 1997 Jul-Aug; 17(4A): 2831-5
- 142) Rauschecker HF., Sauerbrer W., Gatzemeier W., Sauer R., Schauer A., Schmoor C., Schumacher M  
**Eight-year results of a prospective non-randomised study on therapy of small breast cancer. The German Breast Cancer Study Group (GBSG).**  
Eur-J-Cancer. 1998 Feb; 34(3): 315-23
- 143) Ravdin RG, Lewison EF, Slack NH, et al.  
**Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma.**  
Surg Gynecol Obstet (United States), Dec 1970, 131(6) p1055-64
- 144) Recht A  
**Preoperative chemotherapy and breast-conserving therapy: why not everyone?**  
J-Clin-Oncol. 1997 Jul; 15(7): 2479-82
- 145) Reidy, JF .  
**Preoperative localisation of impalpable breast lesions.**  
Bristol-Med-Chir-J. 1989 May; 104(2): 43-5
- 146) Richards M., Sainsbury R., Kerr D  
**Inequalities in breast cancer care and outcome.**  
Br-J-Cancer. 1997; 76(5): 634-8
- 147) Richards M., Sainsbury R., Kerr D  
**Inequalities in breast cancer care and outcome.**  
Br-J-Cancer. 1997; 76(5): 634-8
- 148) Sarrazin D; Hery M; Le M  
**Role de l'irradiation post-operaire systematique dans les cancers du sein operables d'emblee, comportant un envahissement ganglionnaire: etude de 209 observations.]**  
Bull Cancer 1973 Jan-Apr;60(1):31-40 (ISSN: 0007-4551)
- 149) Sauer H  
**Mammakarzinom**  
Krück, Kaufmann et al. Therapie Handbuch. Urban & Schwarzenberg 1992 J16-1 - J16-21
- 150) Sauer H  
**Inflammatorisches Mammakarzinom**  
Tumorzentrum München : Empfehlungen zur Diagnostik, Therapie und Nachsorge.  
Manual Mammakarzinom, 5. Auflage 1994; 147-148

- 151) Schafer P, Alberto P, Forni M, et al.  
**Surgery as part of a combined modality approach for inflammatory breast carcinoma.**  
Cancer (United States), Mar 15 1987, 59(6) p1063-7
- 152) Schmolling J., Maus B., Rezek D., Fimmers R., Holler T., Schuller H., Krebs D  
**Breast preservation versus mastectomy--recurrence and survival rates of primary breast cancer patients treated at the UFK Bonn.**  
Eur-J-Gynaecol-Oncol. 1997; 18(1): 29-33
- 153) Schryver AD  
**The Stockholm breast cancer trial**  
Int J Radiat Oncol Biol Phys (United States), Jul-Aug 1976, 1(7-8) p601-609
- 154) Schwegler N  
**Die Strahlen Therapie des Brustkrebses**  
Symposium Mammakarzinom Sonderdruck Kantonsspital Aarau 1987, 76-111
- 155) Sedlmayer F., Rahim HB., Kogelnik HD., Menzel C., Merz F., Deutschmann H., Kranzinger M  
**Quality assurance in breast cancer brachytherapy**  
Int. J. Radiation Oncology Biol. Phys. 1996 Mar 15; 34 (5): 1133-9
- 156) Seki T., Hachiya J., Nitatori T., Yokoyama K., Fukushima H., Uchigasaki S  
**MR imaging for breast cancer**  
Nippon-Geka-Gakkai-Zasshi. 1996 May; 97(5): 347-56
- 157) Senn HJ:  
**Aktueller Stand der adjuvanten Chemo- und Hormontherapie des operablen Mammakarzinoms**  
Schweiz Rundschau Med (Praxis) 1987; 76: 1193-1199
- 158) Senn HJ:  
**Adjuvante Chemotherapie des Mammakarzinoms, Internationale Übersicht und Schweizer Erfahrungen**  
. Arch Geschwulstforsch. 1986; 56: 425-433.
- 159) Serpell JW., Johnson WR.  
**Pre-operative histological diagnosis of breast cancer.**  
Aust-N-Z-J-Surg. 1997 Jun; 67(6): 325-9
- 160) Shetty MR., Reiman HM Jr  
**Tumor size and axillary metastasis, a correlative occurrence in 1244 cases of breast cancer between 1980 and 1995.**  
Eur-J-Surg-Oncol. 1997 Apr; 23(2): 139-41
- 161) Sikora K  
**Specialist surgeons and survival in breast cancer. Breast cancer is a medical, not a surgical, disease**  
BMJ. 1996 May 4; 312(7039): 1155

- 162) Sizer B., Karp S  
**Specialist surgeons and survival in breast cancer. More centralisation of services is not needed**  
BMJ. 1996 May 4; 312(7039): 1156
- 163) Skaane P  
**Magnetic tomography of the breast**  
Tidsskr-Nor-Laegeforen. 1998 Jun 20; 118(16): 2486-90
- 164) Smart CR, Myers MH, Gloeckler LA  
**Implications from SEER data on breast cancer management.**  
Cancer (United States), Mar 1978, 41(3) p787-9
- 165) Smith CL., Kricker A., Armstrong BK  
**Breast cancer mortality trends in Australia: 1921 to 1994.**  
Med-J-Aust. 1998 Jan 5; 168(1): 11-4
- 166) Sosa JA., Diener-West M., Gusev Y., Choti MA., Lange JR., Dooley WC., Zeiger MA  
**Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer.**  
Ann-Surg-Oncol. 1998 Mar; 5(2): 140-9
- 167) Stanton-AW; Levick-JR; Mortimer-PS  
**Chronic arm edema following breast cancer treatment.**  
Kidney-Int-Suppl. 1997 Jun; 59: S76-81
- 168) Steginga-S; Occhipinti-S; Wilson-K; Dunn-J  
**Domains of distress: the experience of breast cancer in Australia.**  
Oncol-Nurs-Forum. 1998 Jul; 25(6): 1063-70
- 169) Steinberg JL., Trudeau ME., Ryder DE., Fishell E., Chapman JA., McCready DR., Fish EB. et al.  
**Combined fine-needle aspiration, physical examination and mammography in the diagnosis of palpable breast masses: their relation to outcome for women with primary breast cancer [published erratum appears in Can J Surg 1997 Feb;40(1):9]**  
Can-J-Surg. 1996 Aug; 39(4): 302-11
- 170) Stevenson JM., Bochenek P., Jamrozik K., Parsons RW., Byrne MJ  
**Breast cancer in Western Australia in 1989. V: Outcome at 5 years after diagnosis**  
Aust-N-Z-J-Surg. 1997 May; 67(5): 250-5
- 171) Stoll, BA  
**Obesity and breast cancer.**  
Int-J-Obes-Relat-Metab-Disord. 1996 May; 20(5): 389-92
- 172) Takei H., Iino Y., Horiguchi J., Maemura M., Koibuchi Y., Horii Y., Nagaoka H., Matsumoto  
**Age-dependent characteristics of screen-detected patients with breast cancer.**  
Anticancer-Res. 1998 Jul-Aug; 18(4B): 2833-6



- 173) Tavani A., Braga C., La-Vecchia C., Parazzini F., Talamini R., Franceschi S  
**Height and breast cancer risk.**  
Eur-J-Cancer. 1998 Mar; 34(4): 543-7
- 174) Thibodeau J., MacRae J  
**Breast cancer survival: a phenomenological inquiry.**  
ANS-Adv-Nurs-Sci. 1997 Jun; 19(4): 65-74
- 175) Tomasson H., Tomasson K.  
**Oral contraceptives and risk of breast cancer. A historical prospective case-control study.**  
Acta-Obstet-Gynecol-Scand. 1996 Feb; 75(2): 157-61
- 176) Tsuchiya A., Abe R., Kanno M., Ohtake T., Fukushima T., Nomizu T., Kimijima I  
**Role of age as a prognostic factor in breast cancer.**  
Surg Today, 27(3):213-6 1997
- 177) Tzingounis V., Cardamakis E., Ginopoulos P., Argiropoulos G  
**Incidence of benign and malignant breast disorders in women taking hormones (contraceptive pill or hormonal replacement therapy).**  
Anticancer-Res. 1996 Nov-Dec; 16(6C): 3997-4000
- 178) Valagussa P, Bonadonna G, Veronesi U  
**Patterns of relapse and survival in operable breast carcinoma with positive and negative axillary nodes.**  
Tumori (Italy), Jun 30 1978, 64(3) p241-58
- 179) Valdagni R., Italia C., Montanaro P., Ciocca M  
**Quality assurance in early breast cancer treatment: clinical aspects of postoperative, external, whole breast irradiation.**  
Recent-Results-Cancer-Res. 1996; 140: 251-61
- 180) Vanlemmens L., Hebbar M., Peyrat JP., Bonnetterre J  
**Age as a prognostic factor in breast cancer.**  
Anticancer Res, 18(3B):1891-6 1998 May-Jun
- 181) Vatten, L.  
**Female sex hormones increase the risk of breast cancer.**  
Tidsskr-Nor-Laegeforen. 1998 Aug 20; 118(19): 2969-74
- 182) Vicini FA., Horwitz EM., Lacerna MD., Dmuhowski CF., Brown DM., White J., Chen PY et al  
**Long-term outcome with interstitial brachytherapy in the management of patients with early-stage breast cancer treated with breast-conserving therapy.**  
Int-J-Radiat-Oncol-Biol-Phys. 1997 Mar 1; 37(4): 845-52
- 183) Walker RA., Lees E., Webb MB., Dearing SJ  
**Breast carcinomas occurring in young women (< 35 years) are different.**  
Br-J-Cancer. 1996 Dec; 74(11): 1796-800

- 184) Walker RA., Lees E., Webb MB., Dearing SJ.  
**Breast carcinomas occurring in young women (<35 years) are different.**  
Br-J-Cancer. 1996 Dec; 74(11): 1796-800
- 185) Wander HE Nagel GA  
**Mammakarzinom**  
W Zuckschwerdt München 4.Auflage 1986
- 186) Wanebo HJ., Cole B., Chung-M., Vezeridis M., Schepps B., Fulton J., Bland K  
**Is surgical management compromised in elderly patients with breast cancer?**  
Ann-Surg. 1997 May; 225(5): 579-86; discussion 586-9
- 187) Wang H., Thoresen SO., Tretli S  
**Breast cancer in Norway 1970-1993: a population-based study on incidence, mortality and survival**  
Br-J-Cancer. 1998 May; 77(9): 1519-24
- 188) Whitten TM., Fraser HR., Christensen WN., Turk PS  
**Axillary lymph node metastasis in stage T1a breast cancer: a pathologic review of 82 patients**  
Am-Surg. 1997 Feb; 63(2): 144-9
- 189) Williams JG  
**Specialist surgeons and survival in breast cancer. Protocols are important**  
BMJ. 1996 May 4; 312(7039): 1156
- 190) Williams MR, Todd JH, Ellis IO, et al.  
**Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.**  
Br J Cancer (England), Jan 1987, 55(1) p67-73
- 191) Wittekind C, Wagner G  
**TNM-Klassifikation maligner Tumoren**  
5. Auflage Springer Verlag
- 192) Wittekind Ch, Riede  
**Pathologie der Brustdrüse**  
Riede Schäfer Wehner : Spezielle und Allgemeine Pathologie. Thieme Verlag. Stuttgart-Heidelberg New York 989 : 866-877
- 193) Zahl,PH .  
**Breast cancer--incidence, mortality and stage shifting in Norway**  
Tidsskr-Nor-Laegeforen. 1997 Oct 30; 117(26): 3765-7
- 194) Ziegler RG., Hoover RN., Nomura AM., West DW., Wu AH., Pike MC., Lake AJ., Horn-Ross  
**Relative weight, weight change, height, and breast cancer risk in Asian-American women.**  
J-Natl-Cancer-Inst. 1996 May 15; 88(10): 650-660

- 195) Zissiadis Y., Langlands AO., Barraclough B., Boyages J  
**Breast conservation: long-term results from Westmead Hospital.**  
Aust-N-Z-J-Surg. 1997 Jun; 67(6): 313-9

## Curriculum Vitae

Name: Lorenz  
 Vorname: Andreas  
 Geboren am: 20.02.1970 in Hildburghausen  
 Familienstand: verheiratet  
 Nationalität: deutsch

### Ausbildung

1977 – 1987	Ernst Thälmann Grundschule, Hildburghausen
1987 – 1989	Gymnasium „Geschwister Scholl“, Hildburghausen Erlangen der Hochschulreife im Juni 1989
1989 – 1990	Krankenpflegeausbildung, Hennebergkliniken Suhl
1990 – 1991	Ausübung der Krankenpflege, Sozial- und Pflegedienst Berlin bei laufender Bewerbung für die Zulassung zum Studiengang der Humanmedizin
1991 – 1998	Freie Universität Berlin Studium der Humanmedizin März 1994 Ärztliche Vorprüfung April 1995 erster Abschnitt der Ärztlichen Prüfung August 1997 zweiter Abschnitt der Ärztlichen Prüfung Oktober 1998 dritter Abschnitt der Ärztlichen Prüfung
1997 – 1998	Praktisches Jahr im Universitätsklinikum Benjamin Franklin
1999- 2000	Tätigkeit als Arzt im Praktikum in der Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Benjamin Franklin
2000- 2002	Tätigkeit als Assistenzarzt in der Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Benjamin Franklin Berlin
2002-	Tätigkeit als Assistenzarzt in der Klinik für Frauenheilkunde und Geburtshilfe, Zentralklinikum Suhl

Wissenschaftliche Tätigkeiten

- 1994 Arbeit als wissenschaftlicher Mitarbeiter im Rahmen einer Multicenterstudie in der Klinik für Anaesthesiologie und operative Intensivmedizin des Universitätsklinikums Benjamin Franklin bei PD Dr. med. C. Spies und PD Dr. med. W. Schaffartzik
- 1995 Arbeit als wissenschaftlicher Mitarbeiter im Rahmen einer Multicenterstudie in der Klinik für Anaesthesiologie und operative Intensivmedizin des Universitätsklinikums Benjamin Franklin bei PD Dr. med. C. Spies
- 1996 Arbeit als wissenschaftlicher Mitarbeiter im Rahmen einer Multicenterstudie in der Klinik für Anaesthesiologie und operative Intensivmedizin des Universitätsklinikums Benjamin Franklin bei PD Dr. med. Hannemann
- 1997 Arbeit als wissenschaftlicher Mitarbeiter im Rahmen einer klinischen Studie in der Klinik für Anaesthesiologie und operative Intensivmedizin des Universitätsklinikums Benjamin Franklin bei PD Dr. med. W. Schaffartzik
- 1999 Mitarbeit bei einer wissenschaftlichen Studie: „DER SENTINEL NODE BEIM BRUSTKREBS“ unter der Leitung von Prof. Dr. Dr. med. F. Opri in der Klinik für Frauenheilkunde und Geburtshilfe des Universitätsklinikums Benjamin Franklin
- 1999 Initialisierung einer wissenschaftlichen Studie: „Herceptinwirkung bei cerebral metastasiertem Mammakarzinom unter der Leitung von Prof. Dr. Dr. med. F. Opri und PD Dr. med. V. Ragosch in der Klinik für Frauenheilkunde und Geburtshilfe des Universitätsklinikums Benjamin Franklin
- 1999 Mitarbeit bei mehreren klinischen Studie in der Klinik für Frauenheilkunde und Geburtshilfe des Universitätsklinikums Benjamin Franklin unter der Leitung von Prof. Dr. Dr. med. F. Opri

Sonstige Tätigkeiten

- 2000                   Schatzmeister des Bundes für Inkontinenzhilfe und  
Blasentherapie in der Gynäkologie e. V., Geschäftsstelle:  
Universitätsklinikum Benjamin Franklin, Freie Universität Berlin,  
12200 Berlin
- 2000                   Systemadministrator des gynäkologischen und geburtshilflichen  
Dokumentationssystems der Klinik für Frauenheilkunde und  
Geburtshilfe des Universitätsklinikums Benjamin Franklin

Posterpräsentationen / Abstracts

- 23.04.1997           Haß I, Spies C, Hilscher S, Lang P, Lorenz A, Teubner J,  
Schaffartzik W  
NO<sub>2</sub>- PLASMAKONZENTRATION UND MYOKARDIALE  
ISCHEMIE BEI PATIENTEN MIT KORONARER  
HERZKRANKHEIT  
Deutscher Anästhesiekongress, Hamburg
- 06.05.1997           Haß I, Spies C, Hilscher S, Lang P, Lorenz A, Teubner J,  
Schaffartzik W  
NO<sub>2</sub> DECREASE DURING PERIOPERATIVE MYOCARDIAL  
ISSCHEMIA IN PATIENTS WITH CAD  
European society of anesthesiologist anual congress, Lausanne
- 06.05.1997           Spies C, Schilling A, Lippmann J, Kiem E, Öhring R, Lorenz A,  
Specht M, Hennig K, Schaffartzik W  
DER EFFEKT VON MANNIT IM TRAUMATISIERTEN  
HIRNGEWEBE DARGESTELLT MITTELS  
MAGNETRESONANZPROTONENSPECTROSKOPIE  
European society of anesthesiologist anual congress, Lausanne

10.12.1997

Moering S, Haß I, Lorenz A, Schaffartzik W  
IS THERE A PROFIT IN BEDSIDE MONITORING OF CLOTTING  
HMT, aPTT, PT- one AND ACT WITH TAS ANALYZER AND  
HEMOCHRON 401 DURING MAJOR VASCULAR SURGERY ?  
51. pga of new york society of anesthesiologists, new york